Omeros Reports Additional Positive Phase 1 Clinical Data for OMS824 for the Treatment of Cognitive Disorders

[PR Newswire] – SEATTLE, Feb. 11, 2014 /PRNewswire/ — Omeros Corporation (OMER) today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros’ phosphodiesterase 10 (PDE10) program. This clinical trial evaluate more

View todays social media effects on OMER

View the latest stocks trending across Twitter. Click to view dashboard

See who Omeros is hiring next, click here to view